Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients

  • Sanofi SA SNY said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99.
  • Sanofi said the new price would be effective from July 1.
  • The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12 Republicans voting in favor of the measure.
  • Sanofi, meanwhile, says that all commercially insured people are eligible for its co-pay assistance programs, regardless of income or insurance, “which limits out-of-pocket expenses for a majority of people between $0 and $10.” But the company also confirmed that some diabetics taking Sanofi’s insulins would see savings with the House bill.
  • Reuters said that Sanofi, Eli Lilly And Co LLY, and Novo Nordisk A/S NVO make up 90% of the U.S. market for insulin. In 2020, Lilly announced a new co-pay scheme that covers most of its insulin products, capping the out-of-pocket cost for insulin to $35 per month.
  • Price Action: SNY shares are up 1.36% at $52.85 during the market session on the last check Wednesday.
  • Photo by Towfiqu Barbhuiya via Unsplash
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!